UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission file number 1-10526 UNITED-GUARDIAN, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdictio ...

Financial Performance - Net sales for the three months ended September 30, 2021, were $3,179,746, a 36.1% increase from $2,336,360 in the same period of 2020[13] - Net income for the nine months ended September 30, 2021, was $3,542,232, representing a 31.5% increase compared to $2,694,450 for the same period in 2020[13] - For the nine months ended September 30, 2021, total sales reached $10,268,592, up 19% from $8,613,918 in the prior year[46] - Basic earnings per share for the three months ended September 30, 2021, was $0.22, compared to $0.16 for the same period in 2020, marking a 37.5% increase[71] - Diluted earnings per share for the nine months ended September 30, 2021, was $0.77, up from $0.59 in 2020, reflecting a 30.5% increase[71] Expenses and Costs - Research and development expenses increased to $130,742 for the three months ended September 30, 2021, up from $114,836 in the same period of 2020, indicating a focus on innovation[13] - The Company has seen a substantial improvement in sales of its cosmetic ingredients, although still negatively impacted by increased shipping costs and higher raw material costs[84] - The Company experienced increased costs due to supply chain disruptions, affecting packaging and shipping expenses[28] - Operating expenses decreased by $34,622 (7%) for Q3 2021 and by $91,393 (6%) for the first nine months of 2021, mainly due to reduced payroll expenses[105] - Research and development expenses increased by $15,906 (14%) for Q3 2021 and by $17,919 (5%) for the first nine months of 2021, primarily due to higher payroll costs[106] Assets and Liabilities - Total current assets rose to $12,962,153 as of September 30, 2021, compared to $11,246,611 at the end of 2020, reflecting improved liquidity[15] - Cash and cash equivalents increased to $691,921 as of September 30, 2021, from $591,444 at the end of 2020, showing a positive cash flow position[15] - Total liabilities increased to $1,707,217 as of September 30, 2021, compared to $1,414,285 at the end of 2020, indicating a rise in current obligations[17] - The allowance for doubtful accounts receivable was $27,296 as of September 30, 2021, up from $14,017 at the end of 2020[42] - The Company reported total accrued expenses of $1,542,760 as of September 30, 2021, compared to $1,363,457 as of December 31, 2020, indicating an increase of 13.2%[64] Sales and Market Performance - Cosmetic ingredients sales for the three months ended September 30, 2021, were $1,578,650, compared to $550,177 in 2020, representing a 187% increase[46] - Approximately 16% of total sales in Q3 2021 were to customers outside the United States, down from 22% in Q3 2020[46] - Sales for Q3 2021 increased by $843,386 (36%) compared to Q3 2020, and for the first nine months of 2021, sales increased by $1,654,674 (19%) compared to the same period in 2020[94] - Sales of cosmetic ingredients in Q3 2021 rose by $1,028,473 (187%) compared to Q3 2020, primarily driven by a $983,466 (308%) increase in personal care product sales to ASI[95] - Pharmaceutical gross sales decreased by $92,405 (6%) for Q3 2021 and $178,459 (4%) for the first nine months of 2021, mainly due to a decline in Renacidin sales after terminating participation in the Medicaid Drug Rebate Program[97][99] Dividends and Contributions - The company declared dividends of $0.48 per share, totaling $2,204,616 for the nine months ended September 30, 2021, compared to $1,928,969 in the same period of 2020[24] - The Company accrued $87,000 in contributions to the 401(k) defined contribution plan for the nine months ended September 30, 2021, compared to $108,750 for the same period in 2020, indicating a decrease of 19.9%[61] Operational Impact of COVID-19 - The company maintained production throughout the COVID-19 pandemic, with minimal impact on pharmaceutical product sales[28] - The impact of COVID-19 led to a significant decline in sales of cosmetic ingredients in 2020, particularly in China, resulting in excess inventory[122] - Sales of cosmetic ingredients in Q1 2021 were slightly lower than Q1 2020 due to the ongoing effects of the pandemic[124] - The Company is unable to project the future impact of the pandemic on its operations or financial results, although it does not expect impairment of asset carrying values or liquidity[88] - The Company does not expect the pandemic to affect its ability to obtain raw materials or maintain production levels[126] Supply Chain and Raw Material Concerns - The Company anticipates continued supply chain disruptions affecting packaging and shipping costs, as well as raw material prices[125] - Some raw materials have experienced price increases, which may impact future manufacturing costs[126] - The timely shipping of products may continue to be affected by a shortage of truck drivers[126]

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED-GUARDIAN, INC. (Exact Name of Registrant as Specified in Its Charter) Incorporation or Organization) Delaware 11-1719724 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) 230 Marcus Bo ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ COMMISSION FILE NUMBER: 1-10526 UNITED-GUARDIAN, INC.. (Exact Name of Registrant as Specified in Its Charter) Delaware 11-1719724 (State or Other Jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 1O-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission file number 1-10526 UNITED-GUARDIAN, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdictio ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 . ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 1-10526 UNITED-GUARDIAN, INC. . (Exact name of registrant as specified in its charter) incorporation or organization) Delawar ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) Commission File Number: 1-10526 UNITED-GUARDIAN, INC.. (Exact name of registrant as specified in its charter) Delaware 11-1719724 incorporation or organization) (State or other jurisdiction of (I.R.S. Employer Identification No.) 230 Marcus Boulevard, Hauppauge, New York 11788 (Address of principal executive offices) (631) 273-0900 (Registrant's telephone number, including area code) N/A (Former name, former address and form ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ (State or Other Jurisdiction of (I.R.S. Employer Identification No.) 230 Marcus Boulevard, Hauppauge, New York 11788 (Address of Principal Executive Office ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission file number 1-10526 UNITED-GUARDIAN, INC. (Exact name of Registrant as specified in its charter) Delaware 11-1719724 (State ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 1-10526 UNITED-GUARDIAN, INC. (Exact name of registrant as specified in its charter) Delaware 11-1719724 (State or other jurisd ...